Cefazolin

證據等級: L5

預測適應症: 8 個

Cefazolin: From Bacterial Infections to Infectious Otitis Media

One-Sentence Summary

Cefazolin is a first-generation cephalosporin antibiotic widely used as a perioperative surgical prophylactic agent and for the treatment of gram-positive bacterial infections. The TxGNN model predicts it may be effective for Infectious Otitis Media, with 1 clinical trial and 3 publications currently supporting this direction — though significant mechanistic coverage gaps substantially limit its direct applicability to this indication.

Quick Overview

Item	Content
Original Indication	Bacterial infections / Surgical prophylaxis (first-generation cephalosporin; no Philippines registration on record)
Predicted New Indication	Infectious Otitis Media
TxGNN Prediction Score	99.44%
Evidence Level	L3
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacology, Cefazolin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking and triggering autolytic cell death. It demonstrates strong bactericidal activity against gram-positive organisms — particularly Staphylococcus aureus (MSSA), Group A/B Streptococci, and Streptococcus pneumoniae.

The mechanistic link to infectious otitis media is partial. S. pneumoniae, one of the three primary causative organisms in acute otitis media (AOM), falls within cefazolin’s spectrum. However, the other two major AOM pathogens — Haemophilus influenzae and Moraxella catarrhalis — are gram-negative organisms that cefazolin cannot reliably cover. This means effective pathogen coverage is limited to the subset of AOM cases attributable to susceptible gram-positive bacteria, which represents only a fraction of real-world AOM presentations.

An important practical constraint compounds this mechanistic gap: cefazolin is available only as an intravenous or intramuscular formulation, making it unsuitable for standard outpatient AOM management. The strongest evidence niche across all 8 TxGNN-predicted indications in this pack is perioperative prophylaxis for otologic surgery (Middle Ear Disease, rank 3, L2 evidence, “Proceed with Guardrails”), where IV administration is clinically appropriate and gram-positive surgical site infection prevention is the primary goal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01511107	Phase 2b	Terminated	520	Multicenter, randomized, double-blind, placebo-controlled trial comparing 5-day vs. 10-day antimicrobial therapy for AOM in children aged 6–23 months; the trial was terminated early before reaching its endpoints, leaving efficacy conclusions incomplete and substantially reducing the evidential weight

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39567876	2025	Case Series	Ann Otol Rhinol Laryngol	Ceftazidime–cefazolin combination used as empiric therapy for pediatric Gradenigo Syndrome (petrous apicitis secondary to AOM); demonstrates cefazolin’s potential role in severe otitis-related complications requiring IV antibiotics
877649	1977	Review	South Med J	Review of cephalosporin use in pediatric infections, noting efficacy against gram-positive organisms and utility as an alternative in penicillin-hypersensitive patients
3742953	1986	Review	Clinical Pharmacy	Case report and review of Stevens-Johnson syndrome in a child; IV cefazolin was used as part of treatment for concurrent otitis media and upper airway infection, providing indirect evidence of clinical use in this context

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Cefazolin covers only S. pneumoniae among the three major AOM pathogens, lacks coverage against H. influenzae and M. catarrhalis, is formulated exclusively for IV/IM use, and the only relevant clinical trial was terminated early — together these factors leave the infectious otitis media indication without a viable clinical pathway.

To proceed, the following is needed:

Retrieve mechanism of action data from DrugBank API (currently flagged as a High-severity Data Gap)
Obtain the Philippines FDA package insert to assess local safety warnings, contraindications, and approved indications
If the repurposing interest shifts toward otologic surgery prophylaxis rather than acute AOM treatment, pivot the evaluation to the Middle Ear Disease indication (rank 3, L2 evidence, “Proceed with Guardrails”), which has a substantially stronger mechanistic and clinical justification under ASHP/IDSA surgical prophylaxis guidelines
Should an AOM-focused development path remain of interest, prospective clinical data targeting gram-positive AOM subpopulations in hospital settings (where IV administration is feasible) would be required to establish proof of concept
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.